Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097737621> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2097737621 endingPage "586" @default.
- W2097737621 startingPage "S" @default.
- W2097737621 abstract "Background and Aims: Due to recurring nature of GERD, Most patients require long term maintenance therapy and continuous medication of proton pump inhibitor (PPI) is an adequate option for patients with erosive esophagitis. The aim of this study was to evaluate the efficacy and cost minimization analysis of omeprazole 10 mg once daily and rabeprazole 10 mg once daily for 24 weeks in the maintenance of remission Methods:This is randomized, open-label study enrolled 279 patients with erosive esophagitis A or B (LA classification) and typical GERD symptoms. Patients who showed complete endoscopic and symptomatic healing after 8 weeks PPI treatment were randomly allocated to maintenance treatment with omeprazole 10mg once daily or rabeprazole 10mg once daily for 42 weeks. The primary efficacy endpoint was the proportion of patients with symptomatic remission at 42 weeks. Secondary assessments included healing of reflux esophagitis, severity and frequency of reflux symptoms and cost-minimization analysis in the maintenance phase Results:At the end of 42 weeks of maintenance therapy, 96.4% of omeprazole treated and 95.1% of rabeprazole treated patients remained symptom free (P>0.05). Omeprazole and rabeprazole were also similarly efficacious in terms of endoscopic non-relapse rate for RE with 93.3% of patients on omeprazole and 97.5% of patients of rabeprazle. (P>0.05) Two drugs were also comparable with regard to severity and frequency of reflux symptoms duringmaintenance phase. (P>0.05) In the cost-minimization analysis, The mean total costs per patient for remaining symptom free within 6 months was 241,775 won in omeprazole and 287,115 won in rabeprazole, respectively.(as if 24 November 2011, 1 USD= 1,176.33 won) Conclusions:Omeprazole 10mg appeared to have a similar efficacy in maintaining symptomatic remission as rabeprazole 10 mg, but had a lower total cost per patient than rabeprazole 10mg." @default.
- W2097737621 created "2016-06-24" @default.
- W2097737621 creator A5005962936 @default.
- W2097737621 creator A5073284312 @default.
- W2097737621 creator A5077038657 @default.
- W2097737621 creator A5081670222 @default.
- W2097737621 date "2012-05-01" @default.
- W2097737621 modified "2023-10-16" @default.
- W2097737621 title "Mo1066 A Multi-Center, Randomized, Double Blinded, Phase 4 Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compare to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease" @default.
- W2097737621 doi "https://doi.org/10.1016/s0016-5085(12)62246-x" @default.
- W2097737621 hasPublicationYear "2012" @default.
- W2097737621 type Work @default.
- W2097737621 sameAs 2097737621 @default.
- W2097737621 citedByCount "1" @default.
- W2097737621 countsByYear W20977376212023 @default.
- W2097737621 crossrefType "journal-article" @default.
- W2097737621 hasAuthorship W2097737621A5005962936 @default.
- W2097737621 hasAuthorship W2097737621A5073284312 @default.
- W2097737621 hasAuthorship W2097737621A5077038657 @default.
- W2097737621 hasAuthorship W2097737621A5081670222 @default.
- W2097737621 hasBestOaLocation W20977376211 @default.
- W2097737621 hasConcept C126322002 @default.
- W2097737621 hasConcept C168563851 @default.
- W2097737621 hasConcept C2776694085 @default.
- W2097737621 hasConcept C2777498785 @default.
- W2097737621 hasConcept C2778283404 @default.
- W2097737621 hasConcept C2779116819 @default.
- W2097737621 hasConcept C2779134260 @default.
- W2097737621 hasConcept C43270747 @default.
- W2097737621 hasConcept C71924100 @default.
- W2097737621 hasConcept C90924648 @default.
- W2097737621 hasConceptScore W2097737621C126322002 @default.
- W2097737621 hasConceptScore W2097737621C168563851 @default.
- W2097737621 hasConceptScore W2097737621C2776694085 @default.
- W2097737621 hasConceptScore W2097737621C2777498785 @default.
- W2097737621 hasConceptScore W2097737621C2778283404 @default.
- W2097737621 hasConceptScore W2097737621C2779116819 @default.
- W2097737621 hasConceptScore W2097737621C2779134260 @default.
- W2097737621 hasConceptScore W2097737621C43270747 @default.
- W2097737621 hasConceptScore W2097737621C71924100 @default.
- W2097737621 hasConceptScore W2097737621C90924648 @default.
- W2097737621 hasIssue "5" @default.
- W2097737621 hasLocation W20977376211 @default.
- W2097737621 hasOpenAccess W2097737621 @default.
- W2097737621 hasPrimaryLocation W20977376211 @default.
- W2097737621 hasRelatedWork W1972259282 @default.
- W2097737621 hasRelatedWork W2067205465 @default.
- W2097737621 hasRelatedWork W2081841312 @default.
- W2097737621 hasRelatedWork W2095242184 @default.
- W2097737621 hasRelatedWork W2373334508 @default.
- W2097737621 hasRelatedWork W3028691437 @default.
- W2097737621 hasRelatedWork W3031145588 @default.
- W2097737621 hasRelatedWork W66128193 @default.
- W2097737621 hasRelatedWork W3141404013 @default.
- W2097737621 hasRelatedWork W3142083002 @default.
- W2097737621 hasVolume "142" @default.
- W2097737621 isParatext "false" @default.
- W2097737621 isRetracted "false" @default.
- W2097737621 magId "2097737621" @default.
- W2097737621 workType "article" @default.